The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses

Journal of Immunology

Volumn 164, Issue 12, 2000, Pages 6147-6157

  Schwarz, Katrin ^a   De Giuli, Rita ^a   Schmidtke, Gunter ^a   Kostka, Susanne ^b   Van Den Broek, Maries ^c   Bo Kim, Kyung ^d   Crews, Craig M ^d   Kraft, Regine ^b   Groettrup, Marcus ^a  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c INSTITUTE OF EXPERIMENTAL IMMUNOLOGY   (Switzerland)

^d YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LACTACYSTIN; PROTEASOME INHIBITOR;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITION; EPITOPE MAPPING; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0034659804     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.12.6147     Document Type: Article

References (52)

1. Rock, K. L., and A. L. Goldberg. 1999. Degradation of cell proteins and the generation of MHC class I-presented peptides. Annu. Rev. Immunol. 17:739.
2. Paz, P., N. Brouwenstijn, R. Perry, and N. Shastri. 1999. Discrete proteolytic intermediates in the MHC class I antigen processing pathway and MHC I-dependent peptide trimming in the ER. Immunity 11:241.
3. Voges, D., P. Zwickl, and W. Baumeister. 1999. The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu. Rev. Biochem. 68:1015.
4. Groettrup, M., A. Soza, U. Kuckelkorn, and P. M. Kloetzel. 1996. Peptide antigen production by the proteasome: complexity provides efficiency. Immunol. Today 17:429.
5. Groll, M., L. Ditzel, J. Löwe, D. Stock, M. Bochtler, H. D. Bartunik, and R. Huber. 1997. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 386:463.
6. Heinemeyer, W., M. Fischer, T. Krimmer, U. Stachon, and D. H. Wolf. 1997. The active sites of the eukaryotic 20S proteasome and their involvement in subunit precursor processing. J. Biot. Chem. 272:25200.
7. Schmidtke, G., M. Eggers, T. Ruppert, M. Groettrup, U. Koszinowskj, and P. M. Kloetzel. 1998. Inactivation of a defined active site in the mouse 20S proteasome complex enhances MHC class I antigen presentation of a mouse cytomegalovirus protein. J. Exp. Med. 187:1641.
8. Salzmann, U., S. Kral, B. Braun, S. Standera, M. Schmidt, P. M. Kloetzel, and A. Sijts. 1999. Mutational analysis of subunit iβ2 (MECL-1) demonstrates conservation of cleavage specificity between yeast and mammalian proteasomes. FEBS Lett. 454:11.
9. Bogyo, M., S. Shin, J. S. McMaster, and H. L. Ploegh. 1998. Substrate binding and sequence preference of the proteasome revealed by active-site-directed affinity probes. Chem. Biol. 5:307.
10. Rock, K. L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A. L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78:761.
11. Bai, A., and J. Forman. 1997. The effect of the proteasome inhibitor lactacystin on the presentation of transporters associated with antigen processing (TAP)-dependent and TAP-independent peptide epitopes by class I molecules. J. Immunol. 159:2139.
12. Craiu, A., M. Gaczynska, T. Akopian, C. F. Gramm, G. Fenteany, A. L. Goldberg, and K. L. Rock. 1997, Lactacystin and clasto-lactacystin β-lactone modify multiple proteasome β-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation. J. Biol. Chem. 272:13437.
13. Cerundolo, V., A. Benham, V. Braud, S. Mukherjee, K. Gould, B. Macino, J. Neefjes, and A. Townsend. 1997. The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. Eur. J. Immunol. 27:336.
14. Gallimore, A., K. Schwarz, M. van den Broek, H. Hengartner, and M. Groettrup. 1998. The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. Mol. Immunol. 35:581.
15. Vinitsky, A., L. C. Anton, H. L. Snyder, M. Orlowski, J. R. Bennink, and J. W. Yewdell. 1997. The generation of MHC class I-associated peptides is only partially inhibited by proteasome inhibitors: involvement of nonproteasomal cytosolic proteases in antigen processing? J. Immunol. 159:554.
16. Sewell, A. K., D. A. Price, H. Teisserenc, B. L. Booth, U. Gileadi, F. M. Flavin, J. Trowsdale, R. E. Phillips, and V. Cerundolo. 1999. IFN-γ exposes a cryptic cytotoxic T lymphocyte epitope in HIV-1 reverse transcriptase. J. Immunol. 162: 7075.
17. Valmori, D., U. Gileadi, C. Servis, P. R. Dunbar, J. C. Cerottini, P. Romero, V. Cerundolo, and F. Levy. 1999. Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 189:895.
18. Geier, E., G. Pfeifer, M. Wilm, M. LucchiariHartz, W. Baumeister, K. Eichmann, and G. Niedermann. 1999. A giant protease with potential to substitute for some functions of the proteasome. Science 283:978.
19. GilTorregrosa, B. C., A. R. Castano, and M. DelVal. 1998. Major histocompatibility complex class I viral antigen processing in the secretory pathway defined by the trans-Golgi network protease furin. J. Exp. Med. 188:1105.
20. Silva, C. L., F. C. V. Portaro, V. L. D. Bonato, A. C. M. deCamargo, and E. S. Ferro. 1999. Thimet oligopeptidase (EC 3. 4.24.15), a novel protein on the route of MHC class I antigen presentation. Biochem. Biophys. Res. Commun. 255:591.
21. Omura, S., T. Fujimoto, K. Otoguro, K. Matsuzaki, R Moriguchi, H. Tanaka, and Y. Sasaki. 1991. Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells. J. Antibiot. 44:113.
22. Fenteany, G., R. F. Standaert, W. S. Lane, S. Choi, E. J. Corey, and S. L. Schreiber. 1995. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin. Science 268:726.
23. Hanada, M., K. Sugawara, K. Kaneta, S. Toda, Y. Nishiyama, K. Tomita, H. Yamamoto. M. Konishi, and T. Oki, 1992. Epoxomicin, a new antitumor agent of microbial origin. J. Antibiot. 45:1746.
24. Meng, L., R. Mohan, B. H. B. Kwok, M. Elofsson, N. Sin, and C. M. Crews. 1999. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc. Natl. Acad. Sci. USA 96:10403.
25. Gallimore, A., T. Dumrese, H. Hengartner, R. M. Zinkernagel, and H.-G. Rammensee. 1998. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 187:1647.
26. Del Val, M., H.-J. Schlicht, H. Volkmer, M. Messerle, M. J. Reddehase, and U. H. Koszinowski. 1991. Protection against lethal cytomegalovirus infection by a recombinant vaccine containing a single nonameric T-cell epitope. J. Virol. 65:3641.
27. Groettrup, M., T. Ruppert, L. Kuehn, M. Seeger, S. Standera, U. Koszinowski, and P. M. Kloetzel. 1995. The interferon-γ-inducible 11S regulator (PA28) and the LMP2/LMP7 subunits govern the peptide production by the 20S proteasome in vitro. J. Biol. Chem. 270:23808.
28. Aden, D. P., and B. B. Knowles. 1976. Cell surface antigens coded for by the human chromosome 7. Immunogenetics 3:209.
29. Castelmur, L. C. DiPaolo, M. F. Bachmann, H. Hengartner, R. M. Zinkernagel, and T. M. Kündig. 1993. Comparison of the sensitivity of in vivo and in vitro assays for detection of antiviral cytotoxic T cell activity. Cell. Immunol. 151:460.
30. k haplotype. Eur. J. Immunol. 20:1873.
31. Sanderson, S., and N. Shastri. 1994. LacZ inducible, antigen/MHC-specific T cell hybrids. Int. Immunol. 6:369.
32. Lehmann-Grube, F. 1971. Lymphocytic choriomeningitis virus. Virol. Monogr. 10:1.
33. Volkmer, H., C. Bertholet, S. Jonjic, R. Witter, and U. Koszinowski. 1987. Cytolytic T lymphocyte recognition of the murine cytomegalovirus nonstructural immediate-early protein pp89 expressed by recombinant vaccinia virus. J. Exp. Med. 166:668.
34. Bruns, M., J. Cihak, G. Müller, and F. Lehmann-Grube. 1983. Lymphocytic choriomeningitis virus. VI. Isolation of a glycoprotein mediating neutralization. Virology 130:247.
35. Battegay, M., S. Cooper, A. Althage, J. Banziger, H. Hengartner, and R. M. Zinkernagel. 1991. Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates. J. Virol. Methods 31:191.
36. Sin, N., K. B. Kim, M. Elofsson, L. H. Meng, H. Auth, B. H. B. Kwok, and C. M. Crews. 1999. Total synthesis of the potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg. Med. Chem. Lett. 9:2283.
37. Kisselev, A. F., T. N. Akopian, V. Castillo, and A. L. Goldberg. 1999. Proteasome active sites allosterically regulate each other, suggesting a cyclical bite-chew mechanism for protein breakdown. Mol. Cell. 4:395.
38. Schwarz, K., M. van den Broek, R. de Giuli, W. W. Seelentag, N. Shastri, and M. Groettrup. 2000. The use of LCMV-specific T cell hybridomas for the quantitative analysis of MHC class I restricted antigen presentation. J. Immunol. Methods 199:202.
39. Buchmeier, M. J., and R. M. Zinkernagel. 1992. Immunodominant T cell epitope from signal sequence. Science 257:1142.
40. Burns, J. W., and M. J. Buchmeier. 1991. Protein-protein interactions in lymphocytic choriomeningitis virus. Virology 183:620.
41. Schmidtke, G., H. Holzhütter, M. Bogyo, N. Kairies, M. Groll, R. de Giuli, S. Emch, and M. Groettrup. 1999. How an inhibitor of the HIV-1 protease modulates proteasome activity. J. Biol. Chem. 274:35734.
42. André, P., M. Groettrup, P. Klenerman, R. deGiuli, B. L. Booth, V. Cerundolo, M. Bonneville, F. Jotereau, R. M. Zinkernagel, and V. Lotteau. 1998. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. USA 95:13120.
43. Fenteany, G., and S. L. Schreiber. 1998. Lactacystin, proteasome function, and cell fate. J. Biol. Chem. 273:8545.
44. Ostrowska, H., C. Wojcik, S. Omura, and K. Worowski. 1997. Lactacystin, a specific inhibitor of the proteasome, inhibits human platelet lysosomal cathepsin A-like enzyme. Biochem. Biophys. Res. Commun. 234:729.
45. Corey, E. J., and W. D. Z. Li. 1998. An efficient total synthesis of a new and highly active analog of lactacystin. Tetrahedron Lett. 39:7475.
46. Groettrup, M., and G. Schmidtke. 1999. Selective proteasome inhibitors: modulators of antigen presentation? Drug Discovery Today 4:63.
47. Townsend, A., J. Bastin, K. Gould, G. Brownlee, M. Andrew, B. Coupar, D. Boyle, S. Chan, and G. Smith. 1988. Defective presentation to class I-restricted cytotoxic T lymphocytes in vaccinia-infected cells is overcome by enhanced degradation of antigen. J. Exp. Med. 168:1211.
48. Sijts, A. J. A. M., M. S. Villanueva, and E. G. Pamer. 1996. CTL epitopes generation is tightly linked to cellular proteolysis of a Listeria monocytogenes antigen. J. Immunol. 156:1497.
49. Rodriguez, F., J. Zhang, and J. L. Whitton. 1997. DNA immunization: ubiquitination of a viral protein enhances cytotoxic T-lymphocyte induction and antiviral protection but abrogates antibody induction. J. Virol. 71:8497.
50. Goth. S., V. Nguyen, and N. Shastri. 1996. Generation of naturally processed peptide/MHC class I complexes is independent of the stability of endogenously synthesized precursors. J. Immunol. 157:1894.
51. Yewdell, J. W., L. C. Anton, and J. R. Bennink. 1996. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules. J. Immunol. 157:1823.
52. Benham, A. M., M. Gromme, and J. Neefjes. 1998. Allelic differences in the relationship between proteasome activity and MHC class I peptide loading. J. Immunol. 161:83.